| 88.57 1.43 (1.64%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 105.7 | 1-year : | 123.46 |
| Resists | First : | 90.5 | Second : | 105.7 |
| Pivot price | 85.6 |
|||
| Supports | First : | 83.46 | Second : | 79.12 |
| MAs | MA(5) : | 88.15 |
MA(20) : | 85.48 |
| MA(100) : | 89.53 |
MA(250) : | 93.1  |
|
| MACD | MACD : | 0.5 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.5 |
D(3) : | 77.9 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 107.44 | Low : | 79.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZBH ] has closed below upper band by 18.1%. Bollinger Bands are 13.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.91 - 89.4 | 89.4 - 89.86 |
| Low: | 85.6 - 86.25 | 86.25 - 86.85 |
| Close: | 87.62 - 88.57 | 88.57 - 89.44 |
Zimmer Biomet Holdings, Inc. (ZBH), along with its global subsidiaries, operates as a leading player in the musculoskeletal healthcare sector. The company extends its reach across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. ZBH is responsible for the design, manufacturing, and marketing of a wide array of orthopedic reconstructive solutions, including prominent knee and hip replacement systems. Their offerings also encompass Specialized Enabling Technologies (S.E.T.) products, which cover areas such as sports medicine, biologics, foot and ankle care, extremity treatments, and trauma management. Furthermore, the company provides medical devices and surgical instruments specifically for spinal conditions, alongside products for facial and cranial reconstruction. A unique part of their portfolio includes systems designed to stabilize and fixate chest bones, facilitating recovery or reconstruction following open-heart surgery, traumatic injuries, or congenital chest deformities. The company's product lines also feature a comprehensive range of dental solutions, such as reconstructive implants, prosthetics, and regenerative materials. Additionally, they are involved in robotic surgical systems, general surgical instruments, and bone cements. These advanced products and solutions are primarily utilized to address conditions in patients suffering from disorders or injuries affecting bones, joints, and their associated soft tissues. Zimmer Biomet caters to a broad clientele, including orthopedic, neuro-, and oral surgeons, dentists, hospitals, independent distributors, healthcare suppliers, and various other medical specialists. Their network further encompasses agents, healthcare purchasing organizations, and group buying alliances. Originally established in 1927, the enterprise was initially known as Zimmer Holdings, Inc., before rebranding as Zimmer Biomet Holdings, Inc. in June 2015. Its corporate headquarters are situated in Warsaw, Indiana.
Fri, 12 Jun 2026
Equity Investment Corp Decreases Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Thu, 11 Jun 2026
Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Thu, 11 Jun 2026
Does Zimmer Biomet’s Expanding ROSA Platform Reframe Its Orthopedic Innovation Story For Investors (ZBH)? - simplywall.st
Thu, 11 Jun 2026
Brandes Investment Partners LP Raises Position in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Wed, 10 Jun 2026
Why The Narrative Around Zimmer Biomet (ZBH) Is Shifting Without New Analyst Updates - Yahoo Finance
Tue, 09 Jun 2026
Is Zimmer Biomet Holdings, Inc. (ZBH) A Good Stock To Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 193 (M) |
| Shares Float | 193 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 103.5 (%) |
| Shares Short | 9,160 (K) |
| Shares Short P.Month | 10,090 (K) |
| EPS | 3.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 65.52 |
| Profit Margin | 9 % |
| Operating Margin | 19.6 % |
| Return on Assets (ttm) | 4 % |
| Return on Equity (ttm) | 6 % |
| Qtrly Rev. Growth | 9.3 % |
| Gross Profit (p.s.) | 30.49 |
| Sales Per Share | 43.47 |
| EBITDA (p.s.) | 13.33 |
| Qtrly Earnings Growth | 34 % |
| Operating Cash Flow | 1,670 (M) |
| Levered Free Cash Flow | 1,040 (M) |
| PE Ratio | 22.94 |
| PEG Ratio | 0.5 |
| Price to Book value | 1.35 |
| Price to Sales | 2.03 |
| Price to Cash Flow | 10.26 |
| Dividend | 0.23 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|